<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diethylcarbamazine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diethylcarbamazine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Diethylcarbamazine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_pediatric" data-topicid="139259" href="/d/html/139259.html" rel="external">see "Diethylcarbamazine (United States: Available via CDC drug service investigational drug [IND] protocol only): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F49628440"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anthelmintic</li></ul></div>
<div class="block doa drugH1Div" id="F49519267"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Dosages expressed as diethylcarbamazine citrate; some products may alternatively list dosing according to diethylcarbamazine (base). The ratio of diethylcarbamazine citrate to diethylcarbamazine (base) is approximately 2:1.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2976a2bf-88eb-455c-864e-a6865f678a27">Loiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Loiasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment: <b>Oral:</b> 8 to 10 mg/kg/day in 3 divided doses for 21 days; for patients with symptomatic loiasis and microfilarial loads ≥8,000 microfilariae/mL, apheresis or albendazole treatment prior to treatment with diethylcarbamazine is recommended (CDC 2020a). <b>Note:</b> For patients with microfilaria in the blood, some clinicians recommend the following dose-escalating regimen: 50 mg as a single dose on day 1; 50 mg 3 times daily on day 2; 100 mg 3 times daily on day 3; 9 mg/kg/day in 3 divided doses on day 4 to end of treatment course (Drugs for Parasitic Infections 2013). Repeat courses of treatment may be needed to achieve cure (CDC 2020a).</p>
<p style="text-indent:-2em;margin-left:4em;">Prophylaxis: <b>Oral:</b> 300 mg once weekly; continue as long as exposure occurs (CDC 2020a; Drugs for Parasitic Infections 2013; Nutman 1988).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4480ccbc-7d54-4c12-b192-0ce0240b8a31">Lymphatic filariasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lymphatic filariasis (</b>
<i>
<b>W. bancrofti, B. malayi, B. timori)</b></i>
<b>: </b>
<b>Oral: </b>6 mg/kg/day for 1 <b>or</b> 12 days (14 to 21 days in patients with tropical pulmonary eosinophilia); daily dose may be given as a single dose or in 3 divided doses (Andrade 1995; CDC 2020b; Drugs for Parasitic Infections 2013). <b>Note:</b> For patients with microfilaria in the blood, some clinicians recommend the following dose-escalating regimen: 50 mg as a single dose on day 1; 50 mg 3 times daily on day 2; 100 mg 3 times daily on day 3; 6 mg/kg/day in 3 divided doses on day 4 to end of treatment course (Drugs for Parasitic Infections 2013).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990602"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Reduce dose in renal impairment (no specific adjustment is provided) (Adjepon-Yamoah 1982).</p></div>
<div class="block doe drugH1Div" id="F49519269"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F49519268"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="139259" href="/d/html/139259.html" rel="external">see "Diethylcarbamazine (United States: Available via CDC drug service investigational drug [IND] protocol only): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Dosages expressed as diethylcarbamazine citrate; some products may alternatively list dosing according to diethylcarbamazine (base). The ratio of diethylcarbamazine citrate to diethylcarbamazine (base) is approximately 2:1.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="babb4965-10af-4008-9c84-4c4a436cba34">Loiasis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Loiasis, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Patients with microfilarial loads ≥8,000 microfilariae/mL should receive apheresis or treatment with albendazole prior to treatment with diethylcarbamazine (CDC 2020a; <i>Red Book</i> [AAP 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: 8 to 10 mg/kg/day in 3 divided doses for 21 days; repeat courses of treatment may be needed to achieve cure (CDC 2020a; Drugs for Parasitic Infections 2013; <i>Red Book</i> [AAP 2021]). <b>Note:</b> For patients with microfilaria in the blood, some clinicians recommend starting with a lower dosage (eg, 50 mg/day) with gradual increase over 3 days to 9 mg/kg/day in 3 divided doses on day 4 through the end of the 21-day treatment course (Drugs for Parasitic Infections 2013).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4480ccbc-7d54-4c12-b192-0ce0240b8a31">Lymphatic filariasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lymphatic filariasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥18 months and Adolescents: Oral: 6 mg/kg as a single dose <b>or</b> 6 mg/kg/day in 3 divided doses for 12 days; in patients with tropical pulmonary eosinophilia, treat for 14 to 21 days (CDC 2020b; <i>Red Book </i>[AAP 2021]; Simonsen 1995). <b>Note: </b>For patients with microfilaria in the blood, some clinicians recommend starting with a lower dosage (eg, 50 mg/day) with gradual increase over 3 days to 6 mg/kg/day in 3 divided doses on day 4 through the end of the treatment course (Drugs for Parasitic Infections 2013).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51117837"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no recommendations specific for pediatric patients. Based on pharmacokinetics and experience in adult patients, dosage should be reduced in renal impairment. Dose reductions may be needed in patients with diets that promote urinary alkalinization; elimination half-life is prolonged and AUC is increased in alkaline urine (Adjepon-Yamoah 1982).</p></div>
<div class="block dohp drugH1Div" id="F57061424"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no recommendations for patients with hepatic impairment (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F49630625"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, decreased appetite, diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, coma, dizziness, drowsiness, encephalitis (allergic), encephalopathy, fatigue, headache, lassitude, lethargy, meningoencephalitis (helminthic), vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, corneal edema, eye pain, increased intraocular pressure, iridocyclitis, lacrimation, optic neuritis, photophobia, punctate keratitis, visual field defect</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, Mazzotti reaction</p></div>
<div class="block coi drugH1Div" id="F49519249"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Patients with onchocerciasis (CDC 2020a; CDC 2020b).</p></div>
<div class="block war drugH1Div" id="F49519250"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Encephalopathy: When treating loiasis, encephalopathy (sometimes fatal), and other severe neurologic adverse reactions may occur; risk is related to the microfilarial load. Microfilarial load must be tested prior to treatment. Use caution if microfilarial load &gt;2,500 microfilariae/mL; patients with microfilarial loads ≥8,000 microfilariae/mL should have the load reduced through apheresis or treatment with albendazole before initiation of treatment with diethylcarbamazine. Corticosteroid use and/or slow dose escalation has <b>not</b> been shown to decrease the risk of fatal encephalopathy (CDC 2020a; CDC 2020b).</p>
<p style="text-indent:-2em;margin-left:4em;">• Inflammatory reactions: Use in patients with onchocerciasis may precipitate Mazzotti reaction (pruritus, fever, arthralgia). Inflammatory response occurring in the cornea and retina can result in permanent visual damage (McCarthy 2015). Use is contraindicated in patients with onchocerciasis; possibility of co-infection with onchocerciasis should be excluded prior to initiation of treatment with diethylcarbamazine (CDC 2020b).</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin reactions: In patients treated for loiasis, some symptoms of loiasis (eg, Calabar swelling, pruritus) may increase briefly during treatment; concomitant use of antihistamines and corticosteroids during the first week of treatment may decrease these symptoms (CDC 2020a).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disorders: Use with caution in patients with cardiac disorders (WHO [Stuart 2009]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution; dosage reduction recommended (Adjepon-Yamoah 1982).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precaution:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alkaline urine: Elimination half-life is prolonged and AUC is increased in alkaline urine; dose reductions may be needed in patients with diets that promote urinary alkalinization (Adjepon-Yamoah 1982).</p></div>
<div class="block accres drugH1Div" id="F49519244"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Diethylcarbamazine is not commercially available in the US; it is available for the treatment of lymphatic filariasis and tropical pulmonary eosinophilia, and for treatment/prevention of loiasis through the Centers for Disease Control (CDC) Drug Service for patients that meet the eligibility criteria in the Investigational New Drug (IND) protocol. For more information, contact the CDC at 404-718-4745, <a class="__cf_email__" data-cfemail="6d1d0c1f0c1e0419081e2d0e090e430a021b" href="/cdn-cgi/l/email-protection">[email protected]</a> or visit <a href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Flaboratory%2Fdrugservice%2Fformulary.html&amp;token=8fUMx%2BfB4trlY8x%2FMo8Y9Ddj5kItZ1H7qlW%2Fe3GJptY28xGubTU0DXWzUi5nl8%2BCwNhzfAcY95p7Mq5fGdd6Fg%3D%3D&amp;TOPIC_ID=112050" target="_blank">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>.</p></div>
<div class="block adm drugH1Div" id="F49519271"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer after meals (WHO [Stuart 2009]).</p></div>
<div class="block admp drugH1Div" id="F52620923"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer after meals (WHO [Stuart 2009]).</p></div>
<div class="block use drugH1Div" id="F49519247"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Loiasis: </b>Treatment and prophylaxis of loiasis caused by <i>Loa loa.</i></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Lymphatic filariasis: </b>Treatment of lymphatic filariasis caused by <i>Wuchereria bancrofti</i>, <i>Brugia malayi</i>, or <i>Brugia timori.</i></p></div>
<div class="block cyt drugH1Div" id="F46170669"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F46170666"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F49519248"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Outcome data following inadvertent exposure to diethylcarbamazine during pregnancy are limited (Weil 2019; WHO 2006). Use of diethylcarbamazine during pregnancy is not recommended (de Silva 1997; WHO 2006). Filarial infection (<i>W. bancrofti, Loa loa</i>) can be transmitted from mother to fetus during pregnancy (Bal 2015; Momb-Ngoma 2015); eradication of maternal infection prior to pregnancy or delaying treatment until after delivery is recommended (Bal 2015; WHO [Stuart 2009]). Patients who are pregnant should avoid exposure if traveling to infected areas (McGovern 2007).</p></div>
<div class="block brc drugH1Div" id="F49992140"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if diethylcarbamazine is present in breast milk; breastfeeding is not recommended.</p></div>
<div class="block mop drugH1Div" id="F49519273"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function at baseline and periodically during treatment; in patients with loiasis, measure microfilarial load prior to treatment; patients with microfilarial loads ≥8,000 microfilariae/mL treated with albendazole to reduce microfilarial load should have close, frequent monitoring of microfilarial load to confirm reduction before initiation of treatment with diethylcarbamazine (CDC 2020a).</p></div>
<div class="block pha drugH1Div" id="F49519252"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Exact mechanism of action is unknown. Proposed mechanisms include platelet-mediated triggering of release of excretory antigen from microfilariae; alterations of prostaglandin metabolism in microfilariae and host endothelial cells that leads to immobilization by inhibition of parasite cholinergic muscle receptors; disruption of microtubule formation; and alterations in helminth surface membranes that result in enhanced killing by the host immune system (deSilva 1997; McCarthy 2015).</p></div>
<div class="block phk drugH1Div" id="F49519255"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed (de Silva 1997).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Not significant (McCarthy 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 10 to 12 hours (McCarthy 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1 to 2 hours (de Silva 1997).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~50% as unchanged drug; ~10% as metabolite); feces (~10%) (de Silva 1997).</p></div>
<div class="block phksp drugH1Div" id="F51221007"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination half-life is prolonged and urinary excretion is reduced (Adjepon-Yamoah 1982).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49659814"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Hetrazan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Dimazine | Notezine | Remazin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Notezine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Hetrazan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Diethylcarbamazine | Filarzan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Banocide | Banocide forte | Dicarb | Eofil | Hetrazan | Resophyl | Trozan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Supatonin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dcmc</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Hetrazan | Notezine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Notezine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Diethizine | Filadec</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Dec</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-7093114">
<a name="7093114"></a>Adjepon-Yamoah KK, Edwards G, Breckenridge AM, Orme ML, Ward SA. The effect of renal disease on the pharmacokinetics of diethylcarbamazine in man. <i>Br J Clin Pharmac</i>. 1982;13(6):829-834.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/7093114/pubmed" id="7093114" target="_blank">7093114</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7660449">
<a name="7660449"></a>Andrade LD, Medeiros Z, Pires ML, et al. Comparative efficacy of three different diethylcarbamazine regimens in lymphatic filariasis. <i>Trans R Soc Trop Med Hyg</i>. 1995;89(3):319-321. doi:10.1016/0035-9203(95)90561-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/7660449/pubmed" id="7660449" target="_blank">7660449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26225417">
<a name="26225417"></a>Bal M, Sahu PK, Mandal N, et al. Maternal infection Is a risk factor for Early childhood infection in filariasis. <i>PLoS Negl Trop Dis</i>.2015;9(7):e0003955. doi: 10.1371/journal.pntd.0003955.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/26225417/pubmed" id="26225417" target="_blank">26225417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control (CDC). Parasites-Loiasis: Resource for Health Professionals. <a href="https://www.cdc.gov/parasites/loiasis/health_professionals/" target="_blank">http://www.cdc.gov/parasites/loiasis/health_professionals/</a>. Updated January 20, 2015. Accessed September 15, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control (CDC). Parasites-Loiasis: Resource for Health Professionals. <a href="https://www.cdc.gov/parasites/loiasis/health_professionals/" target="_blank">http://www.cdc.gov/parasites/loiasis/health_professionals/</a>. Updated November 24, 2020a. Accessed April 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.4">
<a name="CDC.4"></a>Centers for Disease Control (CDC). Parasites- Lymphatic Filariasis: Guidance for Evaluation and Treatment. <a href="https://www.cdc.gov/parasites/lymphaticfilariasis/health_professionals/dxtx.html" target="_blank">http://www.cdc.gov/parasites/lymphaticfilariasis/health_professionals/dxtx.html</a>. Updated June 14, 2013. Accessed September 15, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control (CDC). Parasites- Lymphatic Filariasis: Guidance for Evaluation and Treatment. <a href="https://www.cdc.gov/parasites/lymphaticfilariasis/health_professionals/dxtx.html" target="_blank">http://www.cdc.gov/parasites/lymphaticfilariasis/health_professionals/dxtx.html</a>. Updated October 26, 2020b. Accessed April 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9129865">
<a name="9129865"></a>de Silva N, Guyatt H, Bundy D. Anthelmintics. A comparative review of their clinical pharmacology. <i>Drugs</i>. 1997;53(5):769-788.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/9129865/pubmed" id="9129865" target="_blank">9129865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diethylcarbamazine.1">
<a name="Diethylcarbamazine.1"></a>Diethylcarbamazine citrate (tablets 100 mg Eisai CO Ltd, Japan) [WHO Public Assessment Report part 4]. https://extranet.who.int/prequal/sites/default/files/NT002part4v1.pdf. Accessed February 16, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diethylcarbamazine.2">
<a name="Diethylcarbamazine.2"></a>Diethylcarbamazine citrate (tablets 100 mg Pfizer, India). https://labeling.pfizer.com/ShowLabeling.aspx?id=14804. Accessed April 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diethylcarbamazine.3">
<a name="Diethylcarbamazine.3"></a>Diethylcarbamazine citrate (tablets 100 mg Sanofi-Aventis, France) [WHO Public Assessment Report part 4]. https://extranet.who.int/prequal/sites/default/files/NT001Part4v1.pdf. Accessed February 16, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drugs.1">
<a name="Drugs.1"></a>Drugs for Parasitic Infections. <i>Med Lett Drugs Ther</i>. 2013;11(suppl):e1-e31.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17367482">
<a name="17367482"></a>McGovern LM, Boyce TG, Fischer PR. Congenital infections associated with international travel during pregnancy. <i>J Travel Med</i>. 2007;14(2):117-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/17367482/pubmed" id="17367482" target="_blank">17367482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McCarthy.1">
<a name="McCarthy.1"></a>McCarthy JS, Moore TA. Drugs for helminths. In: Bennett JE, Dolin R, Blaser MJ, eds. <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases</i>. 8th ed. Elsevier; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25897819">
<a name="25897819"></a>Mombo-Ngoma G, Mackanga JR, Basra A, et al. Loa loa infection in pregnant women, Gabon. <i>Emerg Infect Dis</i>. 2015;21(5):899a-901. doi:10.3201/eid2105.141471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/25897819/pubmed" id="25897819" target="_blank">25897819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3166107">
<a name="3166107"></a>Nutman TB, Miller KD, Mulligan M, et al. Diethylcarbamazine prophylaxis for human loiasis. Results of a double-blind study. <i>N Engl J Med</i>. 1988;319(12):752-756. doi:10.1056/NEJM198809223191204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/3166107/pubmed" id="3166107" target="_blank">3166107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7573711">
<a name="7573711"></a>Simonsen PE, Meyrowitsch DW, Makunde WH, Magnussen P. Selective diethylcarbamazine chemotherapy for control of Bancroftian filariasis in two communities of Tanzania: compared efficacy of a standard dose treatment and two semi-annual single dose treatments. <i>Am J Trop Med Hyg</i>. 1995;53(3):267-272. doi:10.4269/ajtmh.1995.53.267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/7573711/pubmed" id="7573711" target="_blank">7573711</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Stuart MC, Kouimtzi M, Hill SR, eds. WHO Model Formulary 2008. https://apps.who.int/iris/handle/10665/44053. Published 2009.</div>
</li>
<li>
<div class="reference">
                  World Health Organization. Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. Geneva, Switzerland: World Health Organization; 2006. https://apps.who.int/iris/handle/10665/43545
                  </div>
</li>
<li>
<div class="reference">
                  WHO Model Prescribing Information: Drugs Used in Parasitic Disease. 2nd edition. Geneva, Switzerland, World Health Organization; 1995. https://apps.who.int/iris/handle/10665/41765
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31233507">
<a name="31233507"></a>Weil GJ, Bogus J, Christian M, et al; DOLF IDA Safety Study Group. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. <i>PLoS Med</i>. 2019;16(6):e1002839. doi:10.1371/journal.pmed.1002839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/31233507/pubmed" id="31233507" target="_blank">31233507</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 112050 Version 35.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
